ClinConnect ClinConnect Logo
Search / Trial NCT04975334

Opioid Antagonism in Hypogonadotropic Hypogonadism

Launched by STEPHANIE B. SEMINARA, MD · Jul 15, 2021

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Hypogonadotropic Hypogonadism Naloxone

ClinConnect Summary

Assignment: Each study subject will serve as their own control.

Delivery of Interventions:

* Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories.
* During the study, the subjects will undergo the following:

* Period 1: Undergo q10 min blood sampling for up to 12 hours
* Period 2: Undergo q10 min blood sampling for up to 12 hours

* Receive a naloxone bolus followed by a naloxone infusion

Gender

ALL

Eligibility criteria

  • Inclusion
  • Age 18-75 years
  • Confirmed diagnosis of hypogonadotropic hypogonadism
  • Genetic sequencing data available
  • All medical conditions stable and well controlled
  • If applicable, willing to use birth control methods (as approved by a study medical professional) during protocol participation
  • Normal blood pressure (systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg)
  • Negative urine drug screening panel
  • Hemoglobin
  • Women: no less than 0.5 gm/dL below the lower limit of the reference range for normal women
  • Men on adequate testosterone replacement therapy: normal male reference range
  • Men off testosterone replacement therapy: no lower than 0.5 gm/dL below the lower limit of the reference range for normal women
  • For women, negative serum hCG pregnancy test
  • Exclusion
  • Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol
  • Current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis and, if applicable, unwilling to complete an appropriate washout for that particular medication and its method of administration
  • Current or recent use of a medication that affects the opioid pathway
  • Active illicit drug use
  • Excessive alcohol consumption (\> 10 drinks/week)
  • For women, pregnant or breastfeeding

About Stephanie B. Seminara, Md

Dr. Stephanie B. Seminara is a distinguished clinical trial sponsor renowned for her expertise in endocrinology, particularly in reproductive health and hormonal disorders. With a robust background in clinical research and a commitment to advancing medical knowledge, Dr. Seminara leads innovative studies aimed at improving therapeutic outcomes for patients with complex endocrine conditions. Her collaborative approach fosters partnerships with leading research institutions, ensuring the highest standards of ethical practice and scientific rigor in all clinical trials. Through her leadership, Dr. Seminara is dedicated to translating research findings into actionable treatments that enhance patient care and quality of life.

Locations

Boston, Massachusetts, United States

Patients applied

0 patients applied

Trial Officials

Stephanie Seminara, MD

Principal Investigator

Massachusetts General Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials